Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (301-310 of 388) with videos related to

Pageof 39
Sort By:
Clinical Genitourinary Cancer|December 13, 2023
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 StudyFernando Sabino Marques Monteiro, Ondřej Fiala, Francesco Massari, et al.
Journal of Cellular Physiology|September 22, 2010
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastasesDaniele Santini, Giuseppe Perrone, Ilaria Roato, et al.
The Lancet. Oncology|April 30, 2022
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 studyRobert Motzer, Camillo Porta, Boris Alekseev, et al.
Future Oncology (London, England)|May 19, 2018
Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access programSergio Bracarda, Luca Galli, Marco Maruzzo, et al.
Hepatology (Baltimore, Md.)|August 29, 2018
Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular CarcinomaStefania Mantovani, Barbara Oliviero, Andrea Lombardi, et al.
Clinical Genitourinary Cancer|April 5, 2026
Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database ConsortiumMartin Zarba, David Maj, Razane El Hajj Chehade, et al.
Clinical Genitourinary Cancer|May 28, 2018
Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?Roberto Iacovelli, Ugo De Giorgi, Luca Galli, et al.
Annals of Surgical Oncology|December 5, 2014
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitorsMatteo Santoni, Alessandro Conti, Stefano Partelli, et al.
Urologic Oncology|April 3, 2019
The effect of a treatment delay on outcome in metastatic renal cell carcinomaRoberto Iacovelli, Luca Galli, Ugo De Giorgi, et al.
European Urology|August 26, 2019
First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database ConsortiumShaan Dudani, Jeffrey Graham, J Connor Wells, et al.
Pageof 39

Showing results (301-310 of 388) with videos related to

Sort By:
Pageof 39
Clinical Genitourinary Cancer|December 13, 2023
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 StudyFernando Sabino Marques Monteiro, Ondřej Fiala, Francesco Massari, et al.
Journal of Cellular Physiology|September 22, 2010
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastasesDaniele Santini, Giuseppe Perrone, Ilaria Roato, et al.
The Lancet. Oncology|April 30, 2022
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 studyRobert Motzer, Camillo Porta, Boris Alekseev, et al.
Future Oncology (London, England)|May 19, 2018
Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access programSergio Bracarda, Luca Galli, Marco Maruzzo, et al.
Hepatology (Baltimore, Md.)|August 29, 2018
Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular CarcinomaStefania Mantovani, Barbara Oliviero, Andrea Lombardi, et al.
Clinical Genitourinary Cancer|April 5, 2026
Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database ConsortiumMartin Zarba, David Maj, Razane El Hajj Chehade, et al.
Clinical Genitourinary Cancer|May 28, 2018
Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?Roberto Iacovelli, Ugo De Giorgi, Luca Galli, et al.
Annals of Surgical Oncology|December 5, 2014
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitorsMatteo Santoni, Alessandro Conti, Stefano Partelli, et al.
Urologic Oncology|April 3, 2019
The effect of a treatment delay on outcome in metastatic renal cell carcinomaRoberto Iacovelli, Luca Galli, Ugo De Giorgi, et al.
European Urology|August 26, 2019
First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database ConsortiumShaan Dudani, Jeffrey Graham, J Connor Wells, et al.
Pageof 39